Agenus Inc. — Form 10-Q Summary
Business context and reporting period. This unaudited filing covers the quarter and six months ended June 30, 2011; it was filed August 5, 2011. Agenus is a biotechnology company developing cancer and infectious-disease products, principally its Prophage cancer vaccines, HerpV, and the QS-21 vaccine adjuvant. Oncophage was approved in Russia for certain kidney cancer patients; the company reported only modest Russian sales. Most product candidates remained in development, and Agenus had incurred substantial losses since inception.
Financial performance and position
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Revenue | $0.786 million | $0.805 million | $1.458 million | $1.742 million |
| Operating loss | $4.702 million | $4.649 million | $9.724 million | $11.910 million |
| Net loss | $5.758 million | $4.972 million | $11.721 million | $13.783 million |
| Net loss per common share | $0.05 | $0.05 | $0.11 | $0.15 |
| Net cash used in operating activities | Not presented by quarter | Not presented by quarter | $8.671 million | $9.171 million |
- Q2 revenue was almost flat year over year. Six-month revenue declined primarily because of fewer QS-21 shipments; product revenue was zero in 2011 versus $35,000 in 2010. Research and development revenue was $0.786 million for Q2 and $1.458 million for the half-year.
- Q2 R&D expense rose 7% to $2.824 million, while G&A declined 4% to $2.664 million. For the half-year, R&D fell 22% to $5.639 million and G&A fell 12% to $5.543 million, reflecting cost containment and changes in development activity.
- Q2 net loss increased despite lower interest expense: the 2010 quarter included a $1.1 million debt-extinguishment gain, with no similar activity in 2011. The half-year net loss improved as operating expenses and interest expense declined.
- Cash and cash equivalents were $12.016 million at June 30, down $7.766 million from year-end 2010. Current assets were $13.296 million and current liabilities $4.807 million. Stockholders’ deficit was $17.152 million; accumulated deficit was $596.140 million.
- Debt principal outstanding was $36.3 million, including $36.1 million of 8% senior secured convertible notes due August 31, 2014 and $100,000 of 2005 notes due February 2025. The balance-sheet carrying amount for convertible senior notes was $30.458 million; principal and carrying value are not the same measure. The 2006 Notes may be repaid in cash or, subject to limitations, common stock at maturity, and holders retain specified rights to equity in the subsidiary holding QS-21 and HerpV rights.
- Financing cash flow was $0.935 million for the half-year, including $1.288 million net equity-sale proceeds; investing cash flow was a $0.031 million use. Agenus issued additional 2006 Notes for $1.387 million of interest as payment-in-kind.
Material changes, outlook and risks
- Management estimated 2011 net cash burn of $16–18 million, defined as operating cash use plus capital expenditures and dividend payments. It expected available resources, anticipated revenues, and estimated agreement proceeds to meet liquidity needs into 2012, but said it expected to raise additional funds before exhausting cash. Failure to obtain financing or partnerships could force program or operating reductions or threaten continued operations.
- In February 2011, the 2006 Notes’ maturity was extended to August 2014 and their conversion into Agenus common stock was waived. The change eliminated the recorded $755,000 derivative liability and resulted in a $5.580 million debt-to-equity component adjustment. The notes remain secured by subsidiary equity and preserve certain subsidiary-conversion and other holder rights.
- QS-21 licensees had approximately 15 vaccine programs in clinical development, including four in Phase 3. Agenus anticipated possible first product launches containing QS-21 in 2013–2014 and potential royalties, but emphasized that approvals, commercialization, and revenue were uncertain. Licensees control their programs and may discontinue them.
- Prophage G-100 and G-200 were being tested in Phase 2 glioma studies; HerpV had completed Phase 1, and Agenus was considering Phase 2 while seeking a partner. Oncophage’s European application received a negative EMA opinion and was withdrawn. The filing cautioned that subgroup findings and interim clinical results do not assure regulatory approval.
- Nasdaq had notified Agenus that its share price failed the $1.00 minimum bid requirement; as of August 5, 2011, compliance had not been regained. The stated deadline was August 30, 2011. Stockholders had authorized the Board to effect a 1-for-2 to 1-for-10 reverse split, but there was no assurance it would restore or maintain listing.
- The IPO class-action litigation had received final settlement approval and judgment, with insurers expected to pay the allocated settlement and defendants bearing no financial liability; appeals by objectors remained pending. No accrual was recorded. The filing also noted general litigation uncertainty.
- Key risks include limited cash runway, reliance on future financing and collaborators, clinical and regulatory uncertainty, modest Oncophage sales and reimbursement challenges in Russia, manufacturing and supply dependencies, competition, intellectual-property risks, and potential Nasdaq delisting. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Cash runway versus the stated $16–18 million full-year 2011 net cash burn, and whether additional financing was secured after the filing.
- Whether the bid-price requirement was met by August 30, 2011, and whether the Board used its reverse-split authority.
- Current principal, interest terms, and holder rights under the amended 2006 Notes, including the collateral and subsidiary-equity provisions.
- Progress and final results for the Prophage clinical programs, regulatory prospects for Oncophage, and whether QS-21 licensee programs advance toward approval and royalties.
- Actual revenue, payment collection, and distribution arrangements for Oncophage in Russia, as well as QS-21 shipments and supply arrangements.